Status:
NOT_YET_RECRUITING
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)
Lead Sponsor:
Ain Shams University
Conditions:
Lung Cancer
NSCLC
Eligibility:
All Genders
Brief Summary
Lung cancer is one of the most common and serious types of cancer. Lung tumor cells exploit immune checkpoint proteins (ICPs) to maintain immune tolerance and thus promote tumor progression and invasi...
Detailed Description
1\. Introduction 1.1. Background Components of the tumor microenvironment (TME) presented by immune cells, tumor cells, and their derived factors are known as Tumor immune microenvironment (TIME). Tum...
Eligibility Criteria
Inclusion
- Adults over 50 years old with NSCLC.
Exclusion
- Lung cancer patients with any cancer other than NSCLC
- Lung cancer patients with incomplete data or incomplete histopathology diagnosis report.
Key Trial Info
Start Date :
June 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06502249
Start Date
June 1 2026
End Date
September 1 2028
Last Update
July 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab
Cairo, Egypt, 11566